Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2001

View Archived Issues

CS-023 may have advantages over imipenem and meropenem according to preclinical data

Inhibition of PI3K enhances human sperm motility

AGI-1067 advances to phase IIb for treatment of restenosis and atherosclerosis

Targeted anti-Gram-positive oxazolidinone shows promise for resistant infections

Oritavancin phase III data, potential in anthrax infections discussed at ICAAC meeting

Adjunctive therapy with Actimmune in a serious invasive fungal infection

Vasomax amendment submitted in the U.K.

Pharmacia returns U.S. rights to Ambien to Sanofi-Synthelabo

Schering-Plough highlights promising therapeutics in development pipeline

Amylin anticipates filing NDA amendment for Symlin within the next six months

Salix seeks approval for rifaximin in travelers' diarrhea

Tularik presents SAR in a novel class of non-nucleoside anti-HCMV agents at ICAAC meeting

AstraZeneca and Lilly to collaborate on clinical trials with ZD-1839 and gemcitabine combination

Allopurinol reverses mechanoenergetic uncoupling in cardiomyopathy

Muscarinic agonist identified at Acadia reduces intraocular pressure in monkeys

New antiinflammatory steroids useful for asthma and various other conditions

N/OFQ receptor ligands useful as analgesics discovered by GSK

Boehringer Ingelheim patents compounds for asthma and other inflammatory disorders

Glycopeptide antibacterial agents designed by Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...